Clearwater Paper (CLW) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
1 Aug, 2026Executive summary
Net sales for Q2 2026 were $374.8M–$375M, down 4% year-over-year, with an 8% increase in sales volumes driven by food service share gains, but offset by a 9% decline in market pricing.
Net loss from continuing operations was $21M–$21.5M, or $1.33–$1.75 per diluted share, impacted by lower pricing, inflation, and a major maintenance outage.
Adjusted EBITDA was negative $8M–$8.2M, with a margin of -2% to -2.2%, mainly due to lower pricing and maintenance timing.
Major maintenance at Lewiston, Idaho was completed on time and on budget at a direct cost of $22M.
Restructuring at Cypress Bend reduced roles by 20%, targeting $8M–$12M in annual cost savings.
Financial highlights
Net sales for the first six months of 2026 were $735M, down from $770M in 2025.
Adjusted EBITDA for the first six months was negative $6M, compared to positive $70M in 2025.
SG&A expenses were reduced to 5.6% of net sales, below the targeted 6%–7% range.
Net debt reduced by $59M in Q2 and $50M year-to-date, aided by working capital improvements, tax refunds, and insurance recoveries.
Cash and cash equivalents increased to $95.4M at quarter-end from $30.7M at year-end 2025.
Outlook and guidance
Q3 2026 Adjusted EBITDA expected between $20M–$30M, with flat shipments and higher production volumes due to no major outages.
Full-year 2026 revenue guidance is $1.4B–$1.5B, with $10M–$20M in price improvements expected in the second half.
Capital expenditures for 2026 projected at $65M–$75M.
Targeted working capital improvement of $20M–$30M for the year, primarily from inventory.
Early signs of SBS industry improvement, with operating rates forecasted to exceed 90% by year-end.
Latest events from Clearwater Paper
- Net sales fell 5% as lower pricing and higher costs drove a net loss despite volume growth.CLW
Q1 2026 - 2025 saw strong sales growth, cost savings, and major governance and ESG initiatives up for shareholder vote.CLW
Proxy filing - Board recommends approval of all director nominees, auditor, compensation, and governance changes.CLW
Proxy filing - Major transformation, cost savings, and ESG progress drive 2026 proxy proposals and governance.CLW
Proxy Filing - Net sales up 12%, Adjusted EBITDA at $107M, but goodwill impairment drove a net loss.CLW
Q4 2025 - Q3 sales and volumes rose, but margins fell; $100M buyback and debt reduction followed tissue sale.CLW
Q3 2024 - Q2 net sales up 12% but net loss; tissue sale to reduce debt and boost paperboard focus.CLW
Q2 2024 - Augusta mill acquisition boosts scale and reach as high utilization supports strong margins.CLW
Stifel 2024 Cross Sector Insight Conference - Augusta acquisition and tissue sale drove higher sales, debt reduction, and a paperboard focus.CLW
Q4 2024